document
written
french
associ
studi
liver
afef
board
aim
provid
inform
physician
involv
care
patient
liver
diseas
coronaviru
diseas
epidem
base
systemat
review
literatur
rigor
evalu
use
grade
method
recommend
base
feedback
china
avail
form
origin
articl
lettersfor
scientif
evid
often
modestand
rule
put
forward
american
european
hepatolog
societi
french
nation
digest
cancer
thesauru
francophon
transplant
societi
suggest
requir
adjust
accord
geograph
particular
epidem
avail
standard
procedur
access
local
resourc
document
updat
regularli
possibl
accord
evolut
knowledg
characterist
epidem
diseas
link
viru
rapidli
spread
around
world
follow
citi
wuhan
provinc
hubei
european
healthcar
system
face
outbreak
serious
ill
patient
fulli
equip
deal
health
crisi
total
unpreced
unexpect
context
must
readapt
procedur
respect
care
patient
liver
diseas
aim
document
examin
current
known
relationship
liver
anticip
safest
possibl
care
procedur
order
reduc
impact
pandem
patient
liver
diseas
feedback
china
indic
presenc
underli
chronic
liver
diseas
patient
care
infect
increas
transaminas
level
patient
gener
moder
median
uil
higher
level
symptomat
andor
sever
form
andor
requir
intens
care
hospitalis
andor
fatal
date
mechan
involv
unclear
inde
data
suggest
possibl
localis
viru
liver
preliminari
plausibl
elev
liver
enzym
context
infect
could
relat
inflammatori
respons
syndrom
drug
induc
toxic
paracetamol
antibiot
ischemia
liver
viral
myocard
frequent
situat
moreov
serolog
test
hepatotrop
virus
recommend
situat
express
receptor
angiotensinconvert
enzym
receptor
cholangiocyt
fact
popul
believ
risk
sever
form
includ
patient
cirrhosi
autoimmun
hepat
immunosuppress
drug
preand
posttranspl
patient
immunosuppress
therapi
addit
classic
barrier
precaut
regular
hand
wash
soap
water
andor
use
alcoholbas
gel
discard
handshak
hug
extens
expir
prescript
administr
quarter
may
accord
decre
april
implement
social
isol
home
confin
sinc
march
simpl
measur
suggest
exampl
adapt
patient
followup
stabl
patient
ideal
tele
video
consult
automat
temporari
cessat
employ
fragil
patient
whose
employ
would
incompat
telework
http
direct
admiss
patient
noncovid
unit
withdraw
visit
rel
hospitalis
patient
recommend
care
protect
patient
continu
care
safe
condit
avoid
movement
free
healthcar
facil
function
allow
receiv
concentr
medic
paramed
resourc
seriou
patient
without
potenti
adjust
etiolog
treatment
liver
diseas
hbv
continu
ongo
analog
treatment
initi
emerg
case
cirrhosi
reactiv
situat
high
transmiss
risk
drug
user
migrant
live
crowd
condit
etc
hcv
continu
ongo
direct
antivir
treatment
gener
rule
defer
treatment
initi
end
social
isol
wait
patient
repeat
barrier
precaut
except
emerg
situat
high
risk
transmiss
ongo
drug
user
migrant
live
overcrowd
condit
etc
hdv
continu
ongo
bulevirtid
therapi
combin
temporari
use
authoris
cohort
framework
gener
rule
postpon
therapi
initi
end
social
isol
wait
patient
recommend
repeat
advic
regard
strict
patient
confin
barrier
precaut
deleg
possibl
third
parti
monthli
retriev
treatment
hospit
pharmaci
latter
dispatch
carri
monthli
checkup
home
visit
regist
nurs
alcohol
advis
consumpt
moder
includ
day
abstin
per
week
take
advantag
confin
begin
abrupt
withdraw
could
requir
hospit
care
ongo
immunosuppress
treatment
continu
without
chang
dosag
treatment
initi
acut
autoimmun
hepat
discuss
casebycas
basi
accord
region
epidem
necessari
togeth
local
compet
centr
option
prefer
aih
treatment
french
refer
centr
corticosteroid
therapi
prednisolon
mgkgday
budesonid
mgday
nonsever
form
delay
onset
immunosuppress
regimen
gener
rule
liver
transplant
recipi
continu
immunosuppress
therapi
without
chang
exclus
patient
comorbid
i
employ
guarante
possibl
telework
http
continu
primari
secondari
prophylaxi
patient
ascit
clinic
signific
portal
hypertens
andor
encephalopathi
essenti
avoid
hospitalis
presenc
requir
diagnosi
pretreat
consult
liver
cancer
new
patient
clinic
signific
sign
jaundic
increas
serum
alat
level
time
upper
limit
normal
valu
recent
hepat
decompens
screen
sign
come
hospit
recept
desk
bodi
temperatur
taken
arriv
doubt
screen
ideal
arriv
depart
accord
facil
standard
procedur
patient
wear
surgic
mask
resourc
permit
soon
arriv
medic
facil
implement
barrier
precaut
disinfect
equip
seat
handl
etc
patient
avoid
wait
group
reduc
wait
time
wait
room
elimin
newspap
maintain
minim
metr
distanc
patient
frequent
ventil
wait
room
enforc
strongli
possibl
rule
concern
hygien
protect
nurs
staff
reschedul
stay
andor
nonurg
procedur
region
heavili
impact
outbreak
peak
plateau
phase
carri
urban
area
mobilis
avail
resourc
otherwis
postpon
approxim
averag
delay
month
period
surveil
imag
previou
hcc
current
hcc
treatment
biannual
screen
hcc
high
risk
patient
nonurg
liver
biopsi
measur
liver
stiff
andor
cap
cautiou
defer
pretranspl
checkup
possibl
accord
riskbenefit
balanc
perform
test
outsid
hospit
depend
local
resourc
mainten
schedul
stay
within
noncovid
unit
ensur
admiss
patient
present
sign
extra
care
protect
surgic
mask
soon
arriv
facil
implement
barrier
precaut
avoid
wait
group
especi
admiss
wait
room
reduc
wait
time
singl
room
possibl
maintain
minim
metr
distanc
patient
appli
hygien
rule
nurs
staff
limit
number
health
carer
involv
follow
main
indic
cur
treatment
primari
liver
cancer
surgeri
intervent
radiolog
ascit
paracentesi
esophag
varic
ligat
gastric
varic
sclerotherapi
secondari
prevent
urgent
liver
biopsi
defer
inclus
end
confin
possibl
except
trial
non
observ
trial
assess
individu
benefitrisk
balanc
casebycas
basi
evalu
promot
possibl
carri
remot
consult
blood
sampl
home
regist
nurs
home
dispatch
treatment
investig
absenc
immun
pneumococcu
carri
pneumococc
polysaccharid
conjug
vaccin
adsorb
jeopardis
confin
otherwis
defer
end
social
isol
hospitalis
non
unitdepart
ensur
admiss
patient
present
sign
take
patient
temperatur
arriv
perform
thorac
ct
scan
screen
prior
admiss
event
unexplain
recent
hepat
decompens
favour
direct
admiss
without
prior
passag
emerg
depart
take
measur
avoid
contamin
surgic
mask
patient
soon
arriv
unit
hand
wash
use
alcoholbas
gel
implement
barrier
precaut
avoid
wait
group
particularli
admiss
reduc
wait
time
maintain
minim
metr
distanc
patient
appli
hygien
rule
nurs
staff
limit
number
nurs
staff
involv
care
visit
remain
authoris
nb
strict
measur
proven
effect
term
mortal
among
chines
patient
decompens
cirrhosi
hospitalis
ambulatori
protect
much
possibl
healthcar
staff
noncovid
patient
contamin
care
patient
safe
condit
potenti
adjust
etiolog
treatment
liver
diseas
hbv
continu
ongo
analog
treatment
initi
emerg
situat
cirrhosi
reactiv
patient
condit
permit
hcv
continu
ongo
direct
antivir
treatment
patient
condit
permit
defer
treatment
initi
wait
patient
hdv
continu
decreas
dosag
ongo
antivir
treatment
bulevirtid
combin
temporari
use
authoris
cohort
framework
casebycas
accord
sever
impact
liver
diseas
individu
riskbenefit
balanc
outpati
treatment
continu
imper
repeat
strict
advic
regard
confin
barrier
precaut
deleg
possibl
third
parti
monthli
retriev
treatment
hospit
pharmaci
monthli
checkup
carri
home
regist
nurs
absenc
hospitalis
patient
impair
renal
function
clearanc
andor
decompens
liver
diseas
bulevirtid
discontinu
possibl
continu
reduct
dosag
immunosuppress
treatment
must
discuss
casebycas
basi
accord
sever
infect
individu
benefitrisk
balanc
internistinfecti
diseas
specialistintens
care
staff
one
hand
hepatologist
hand
togeth
necessari
help
local
compet
centr
french
refer
centr
corticosteroid
decreas
dosag
may
discuss
necessari
maintain
dose
least
mgday
avoid
adren
insuffici
immunosuppress
azathioprin
mycophenol
acid
may
reduc
necessari
especi
patient
lymphopenia
bacteri
fungal
superinfect
lung
aggrav
relat
liver
transplant
recipi
sever
form
sign
requir
oxygen
patient
year
sinc
transplant
discontinu
corticosteroid
treatment
unless
high
immunolog
risk
reject
recurr
autoimmun
diseas
case
corticosteroid
need
reduc
maintain
mgday
discontinu
mycophenol
acid
azathioprin
immunosuppress
therapi
resum
viral
recoveri
dose
prior
cessat
continu
treatment
tacrolimu
target
residu
blood
concentr
ngml
continu
treatment
cyclosporin
target
residu
blood
concentr
ngml
target
blood
concentr
ngml
hour
intak
patient
treat
mtor
inhibitor
patient
tacrolimu
mtor
inhibitor
dual
therapi
discontinu
mtor
inhibitor
treatment
resum
treatment
follow
recoveri
dose
prior
cessat
mainten
tacrolimu
treatment
target
residu
blood
concentr
ngml
patient
mycophenol
acid
mtor
inhibitor
dual
therapi
halv
dosag
mycophenol
acid
continu
mtor
inhibitor
treatment
target
residu
blood
concentr
ngml
resumpt
recoveri
dose
prior
cessat
patient
treat
corticosteroid
treatment
due
high
immunolog
risk
reject
recurr
autoimmun
diseas
maintain
corticosteroid
dose
discontinu
mycophenol
acid
treatment
resumpt
recoveri
dose
prior
cessat
patient
treat
calcineurin
inhibitor
maintain
tacrolimu
cyclosporin
dose
patient
treat
mtor
inhibitor
patient
tacrolimu
mtor
inhibitor
dual
therapi
discontinu
mtor
inhibitor
treatment
resum
treatment
follow
recoveri
dose
prior
cessat
maintain
tacrolimu
cyclosporin
treatment
dose
patient
mycophenol
acid
mtor
inhibitor
dual
therapi
discontinu
mycophenol
acid
treatment
resum
treatment
follow
recoveri
dose
prior
cessat
continu
mtor
inhibitor
treatment
dose
patient
mycophenol
acid
mtor
inhibitor
monotherapi
continu
treatment
dose
resumpt
preinfecti
episod
treatment
symptom
onset
daili
selfmonitor
temperatur
dyspnea
chest
pain
regular
phone
call
doctor
patient
respons
exampl
import
given
correspond
acut
phase
home
confin
day
onset
symptom
outing
mask
onset
symptom
inpati
requir
oxygen
andor
lymphophen
maintain
corticosteroid
dose
mgday
prednison
equival
discontinu
remain
immunosuppress
therapi
patient
high
immunolog
risk
close
transplant
date
present
lymphopenia
continu
treatment
calcineurin
inhibitor
target
residu
blood
concentr
et
ngml
tacrolimu
ngml
ngml
hour
intak
cyclosporin
resum
preinfecti
episod
treatment
soon
oxygen
therapi
withdrawn
maintain
corticosteroid
dose
mgday
prednison
equival
discontinu
remain
immunosuppress
therapi
resum
tacrolimu
ngml
dosag
within
hour
ventil
withdraw
resum
pretreat
soon
viral
recoveri
occur
take
account
prolong
durat
viral
excret
gener
mesur
limit
use
paracetamol
antipyret
purpos
gday
especi
patient
cirrhosi
andor
excess
alcohol
consumpt
formal
contraind
use
nsaid
verifi
drug
interact
standard
treatment
liver
diseas
use
annex
due
potenti
sever
liver
damag
among
patient
magnitud
interact
may
signific
caution
must
taken
limit
diagnost
therapeut
endoscopi
emerg
gastrointestin
haemorrhag
bacteri
cholang
vital
emerg
optimis
nutrit
care
prescript
least
oral
nutrit
supplement
per
day
patient
eat
except
intens
care
unit
limit
care
patient
receiv
care
gener
popul
without
sign
sever
patient
care
home
strict
confin
suspect
need
hospitalis
confirm
attend
physician
andor
staff
within
emerg
unit
andor
emerg
medic
servic
patient
need
test
pcr
andor
thorac
ct
without
sign
sever
infect
patient
care
home
isol
close
monitor
followup
procedur
decid
base
medic
assess
simpl
selfmonitor
symptom
without
need
plan
consult
medic
followup
tele
video
consult
prefer
possibl
day
day
monitor
reinforc
followup
home
regist
nurs
patient
risk
unabl
selfmonitor
patient
visit
consult
must
notifi
healthcar
staff
arriv
report
condit
wear
mask
far
upstream
possibl
gener
procedur
patient
care
unitdepart
possibl
within
facil
patient
alreadi
known
routin
followedup
hepatolog
team
usual
take
care
